PURPOSE: To evaluate and compare the protective effect of tauroursodeoxycholic acid (TUDCA) on photoreceptor degeneration in different models of retinal degeneration (RD) in mice. METHODS: Bbs(M390R/M390R) mice were injected subcutaneously twice a week, from P40 to P120, and rd10 mice were injected every 3 days from P6 to P38 with TUDCA or vehicle (0.15 M NaHCO(3)). Rd1 and rd16 mice were injected daily from P6 to P30 with TUDCA or vehicle. Retinal structure and function were determined at multiple time points by electroretinography (ERG), optical coherence tomography (OCT), and histology. RESULTS: The amplitude of ERG b-waves was significantly higher in TUDCA-treated Bbs1 and rd10 animals than in controls. Retinal thickness on OCT was slightly greater in treated Bbs1 animals than in the controls. Histologically, outer segments were preserved, and the outer nuclear layer was significantly thicker in the treated Bbs1 and rd10 mice than in the controls. Bbs1(M390R/M390R) mice developed less obesity than the control Bbs1(M390R/M390R) while receiving TUDCA. The Rd1 and rd16 mice showed no improvement with TUDCA treatment, and the rd1 mice did not have normal weight gain during treatment. CONCLUSIONS: TUDCA treatment preserved ERG b-waves and the outer nuclear layer in Bbs1(M390R/M390R) mice, and prevented obesity assessed at P120. TUDCA treatment preserved ERG b-waves and the outer nuclear layer in the rd10 mice to P30. TUDCA is a prime candidate for treatment of humans with retinal degeneration, especially those with Bardet-Biedl syndrome, whom it may help not only with the vision loss, but with the debilitating obesity as well.
PURPOSE: To evaluate and compare the protective effect of tauroursodeoxycholic acid (TUDCA) on photoreceptor degeneration in different models of retinal degeneration (RD) in mice. METHODS: Bbs(M390R/M390R) mice were injected subcutaneously twice a week, from P40 to P120, and rd10mice were injected every 3 days from P6 to P38 with TUDCA or vehicle (0.15 M NaHCO(3)). Rd1 and rd16 mice were injected daily from P6 to P30 with TUDCA or vehicle. Retinal structure and function were determined at multiple time points by electroretinography (ERG), optical coherence tomography (OCT), and histology. RESULTS: The amplitude of ERG b-waves was significantly higher in TUDCA-treated Bbs1 and rd10 animals than in controls. Retinal thickness on OCT was slightly greater in treated Bbs1 animals than in the controls. Histologically, outer segments were preserved, and the outer nuclear layer was significantly thicker in the treated Bbs1 and rd10mice than in the controls. Bbs1(M390R/M390R) mice developed less obesity than the control Bbs1(M390R/M390R) while receiving TUDCA. The Rd1 and rd16 mice showed no improvement with TUDCA treatment, and the rd1mice did not have normal weight gain during treatment. CONCLUSIONS:TUDCA treatment preserved ERG b-waves and the outer nuclear layer in Bbs1(M390R/M390R) mice, and prevented obesity assessed at P120. TUDCA treatment preserved ERG b-waves and the outer nuclear layer in the rd10mice to P30. TUDCA is a prime candidate for treatment of humans with retinal degeneration, especially those with Bardet-Biedl syndrome, whom it may help not only with the vision loss, but with the debilitating obesity as well.
Authors: Seongjin Seo; Lisa M Baye; Nathan P Schulz; John S Beck; Qihong Zhang; Diane C Slusarski; Val C Sheffield Journal: Proc Natl Acad Sci U S A Date: 2010-01-04 Impact factor: 11.205
Authors: Jeffrey H Boatright; Anisha G Moring; Clinton McElroy; Michael J Phillips; Vi T Do; Bo Chang; Norm L Hawes; Amber P Boyd; Sheree S Sidney; Rachael E Stewart; Steven C Minear; Rajashree Chaudhury; Vincent T Ciavatta; Cecilia M P Rodrigues; Clifford J Steer; John M Nickerson; Machelle T Pardue Journal: Mol Vis Date: 2006-12-29 Impact factor: 2.367
Authors: Umut Ozcan; Erkan Yilmaz; Lale Ozcan; Masato Furuhashi; Eric Vaillancourt; Ross O Smith; Cem Z Görgün; Gökhan S Hotamisligil Journal: Science Date: 2006-08-25 Impact factor: 47.728
Authors: B Chang; N L Hawes; M T Pardue; A M German; R E Hurd; M T Davisson; S Nusinowitz; K Rengarajan; A P Boyd; S S Sidney; M J Phillips; R E Stewart; R Chaudhury; J M Nickerson; J R Heckenlively; J H Boatright Journal: Vision Res Date: 2007-01-30 Impact factor: 1.886
Authors: Shuhua Song; Jack J N Liang; Michael L Mulhern; Christian J Madson; Toshimichi Shinohara Journal: Cell Stress Chaperones Date: 2011-03-06 Impact factor: 3.667
Authors: C Dirk Keene; Cecilia M P Rodrigues; Tacjana Eich; Manik S Chhabra; Clifford J Steer; Walter C Low Journal: Proc Natl Acad Sci U S A Date: 2002-07-29 Impact factor: 11.205
Authors: James E Heubi; David A Wiechmann; Vivian Creutzinger; Kenneth D R Setchell; Robert Squires; Robert Couser; Philip Rhodes Journal: J Pediatr Date: 2002-08 Impact factor: 4.406
Authors: I A Viringipurampeer; X Shan; K Gregory-Evans; J P Zhang; Z Mohammadi; C Y Gregory-Evans Journal: Cell Death Differ Date: 2014-01-10 Impact factor: 15.828
Authors: Seongjin Seo; Robert F Mullins; Alina V Dumitrescu; Sajag Bhattarai; Daniel Gratie; Kai Wang; Edwin M Stone; Val Sheffield; Arlene V Drack Journal: Invest Ophthalmol Vis Sci Date: 2013-09-11 Impact factor: 4.799
Authors: Steven B Heymsfield; Nicole M Avena; Leslie Baier; Phillip Brantley; George A Bray; Lisa C Burnett; Merlin G Butler; Daniel J Driscoll; Dieter Egli; Joel Elmquist; Janice L Forster; Anthony P Goldstone; Linda M Gourash; Frank L Greenway; Joan C Han; James G Kane; Rudolph L Leibel; Ruth J F Loos; Ann O Scheimann; Christian L Roth; Randy J Seeley; Val Sheffield; Maïthé Tauber; Christian Vaisse; Liheng Wang; Robert A Waterland; Rachel Wevrick; Jack A Yanovski; Andrew R Zinn Journal: Obesity (Silver Spring) Date: 2014-02 Impact factor: 5.002